NYHA Class | Symptoms |
---|---|
I | Cardiac disease, but no symptoms and no limitation in ordinary physical activity, e.g. no shortness of breath when walking, climbing stairs etc. |
II | Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. |
III | Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20–100 m). Comfortable only at rest. |
IV | Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. |
For additional warnings and precautions, see full prescribing information for individual drugs.
For additional warnings and precautions, see full prescribing information for individual drugs.
You must answer all required questions (indicated by the orange asterisk *) in order for the app to determine advice for this patient.
Terms of Service
Click the Terms tab at the bottom of the app before using TreatHF (“the Product”) to read the full Terms of Service and License Agreement (the “Agreement”) which governs the use of the Product. The Agreement includes, among other detailed terms and conditions, certain disclaimers of warranties by the American College of Cardiology Foundation (“ACCF”) and requires the user to agree to release ACCF from any and all liability arising in connection with your use of the Product. By using the Product, you accept and agree to be bound by all of the terms and conditions set forth in the Agreement, including such disclaimers and releases. If you do not accept the terms and conditions of the Agreement, you may not proceed to use the Product. The Agreement is subject to change from time to time, and your continued use of the Product constitutes your acceptance of and agreement to be bound by any revised terms of the Agreement.
About TreatHF
How to Use TreatHF
If ARNI/ACEI/ARB not indicated for this patient:
If beta blocker not indicated for this patient:
Below are suggested next steps for this patient based on the entered indications. Indications collected in this app represent only those covered by ACC/AHA/HFSA guidelines, and should serve as a starting point. Final treatment decisions should be made after a full evaluation of the patient and discussion of patient preferences. In addition, the scope of this app focuses on pharmacological treatment for HFrEF. However, medical therapy should be considered and implemented as just one component of the comprehensive management of a heart failure patient, along with suitable lifestyle management, specialty referrals, and any other treatment as needed.
To help optimize use of medical therapy, review expert consensus guiding principles.
You are now being redirected to the browser to print which should show you the print dialog.
After printing, use the back button on top left to come back to the app.
* Text within this section labeled with (EC) is derived from ACC expert consensus decision
pathways.
Text within this section labeled with (GL) is derived from ACC/AHA clinical
guidelines.
Text in the “Guideline Recommendations” section of each table represents verbatim
guideline recommendations.
Heart Failure Medicine Tips to Remember
Drug Options for Patients With Heart Failure
Protect Your Heart With the Vaccines You Need
Keeping a Vaccine Record is Important – Even for Adults
How Flu Affects Your Heart: Why Getting a Flu Shot is Important
Have Heart Disease? Take Steps to Avoid the Flu
Heart Failure Hospitalization Toolkit
Heart Failure Hospitalization Interactive Pathway
Heart Failure Clinical Topic Collection
Hospital to Home (H2H) Initiative
Advancing Adult Immunization - American College of Cardiology (acc.org)
Clinical Mobile and Web App Collection
Maddox T, Januzzi, J, Allen L, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2021;77:772–810.
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/ AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70:776–803
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62: e147–239.
Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022 May, 79 (17) e263–e421.
Amsterdam E, Wenger N, Brindis R, et al. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. J Am Coll Cardiol. 2014 Dec, 64 (24) e139–e228.
Elissa Driggin, Thomas M. Maddox, Keith C. Ferdinand, et al. ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. Volume 77, Issue 15, 2021, Pages 1938-1948, ISSN 0735-1097.
March 2024
The app was updated in March 2021 to include content from the 2021 Update to the 2017 Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment. New content includes information regarding angiotensin receptor-neprilysin inhibitors (ARNIs) and sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Click here to fill out our feedback survey
This app is meant for use by clinicians in regards to chronic, symptomatic, heart failure patients with reduced ejection fraction (stage C HFrEF).
TreatHF helps clinicians determine which therapies are suggested for their patients with stage C HFrEF and provides guidance on the use of each therapy.
To use the app:
Information in this app is derived from the 2021 Update to the 2017
Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment, the 2017 ACC/ AHA/HFSA Focused
Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure, and the 2013 ACCF/AHA Guideline for
the Management of Heart Failure. Indications collected in the app reflect the evidence-based
indications outlined in these documents, and are meant to serve as a starting point. They do not
represent the full list of considerations for prescribing and optimizing a medication or other clinical
therapy, nor do they take into account contraindications. Use of this app assumes clinicians will
conduct a full evaluation of the patient, consult relevant medical specialists as needed, utilize a team
based approach to optimize therapy, and consider patient preferences in all medical decision making.
The information and recommendations in this app are meant to support clinical decision making. They are
not meant to represent the only or best course of care, or replace clinical judgment. Therapeutic
options should be determined after discussion between the patient and their care provider.
App content and design was refined and vetted by ACC member clinicians, and through user testing with
clinicians practicing in relevant specialties.
TreatHF was developed as part of an ongoing effort at the ACC to facilitate access and implementation of
ACC clinical policy at the point of care, and as part of ACC’s Succeed in Managing Heart Failure (SIMHF)
Initiative, a multi-disciplinary quality program designed to improve care for heart failure patients.
SIMHF is supported by Novartis.
For Support
Call: (202) 375-6000, ext. 5603 or (800) 253-4636
Email: membercare@acc.org
TreatHF Terms of Service and License Agreement
This Terms of Service and License Agreement constitutes a legal agreement (collectively, the "Agreement") between the American College of Cardiology Foundation ("ACCF") and You and your agents ("You") for the use of the TreatHF (the "Product"), whether You use the mobile application version of the Product or the web version of the Product. The Product allows You to access certain content included in the Product ("Content") relating to suggested use of therapies to help treat chronic symptomatic heart failure with reduced ejection fraction.
By using the Product, You accept and agree to be bound by all of the terms and conditions set forth in this Agreement. If You do not wish to accept the terms and conditions of this Agreement, You may not proceed to use the Product.
ACCF may change the terms of this Agreement from time to time without further notice directly to You. When the terms are changed, ACCF will post a general conspicuous notice. If You do not agree with the revised terms, please discontinue use of the Product immediately. Your continued use of the Product following such notice constitutes your acceptance of and agreement to be bound by any revised terms of the Agreement. This Agreement expressly incorporates by reference and includes rules or disclaimers that may be posted and updated within the Product or communicated to You from time to time.
Term and Termination
ACCF may terminate your access and/or the Product at any time. You agree that any termination of your access to the Product shall not result in any liability or other obligation of ACCF to You, or any third party in connection with such termination.
Intellectual Property Rights
This Product, including the information, text, graphics, images, audio and video files, trademarks and
other materials that may be contained therein (collectively "Content"), is owned by ACCF and/or its
suppliers and is protected by patents, copyrights, trademarks, and other proprietary rights. Except as
specifically provided in this Agreement, your use of the Product shall be governed and constrained by
applicable patent, copyright, trademark and other intellectual property laws.
ACCF grants You a limited, nonexclusive, nontransferable, revocable license to utilize and access the
Product for your noncommercial, personal use according to the terms and conditions in this Agreement.
You may not modify, publish, transmit, participate in the transfer or sale of, reproduce, create
derivative works from, distribute, perform, display, incorporate into another website, or in any other
way exploit the Service and/or any of the Content, in whole or in part. Except as expressly granted by
this Agreement, You acquire no right, title or interest in the Product or the Content or other data or
materials incorporated in the Product. ACCF, ACC or affiliates or licensors thereof shall retain all
right, title and interest in the Product and Content.
Limitation of Liability
TO THE FULLEST EXTENT ALLOWED BY APPLICABLE LAW, ACCF HEREBY DISCLAIMS, AND IN NO EVENT SHALL ACCF OR ANY PARTY INVOLVED IN CREATING OR PRODUCING THE PRODUCT BE LIABLE FOR, ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL, OR EXEMPLARY DAMAGES, INCLUDING WITHOUT LIMITATION, DAMAGES FOR LOSS OF PROFITS, GOODWILL, USE, DATA LOSS, OR OTHER LOSSES, WHETHER IN AN ACTION OF CONTRACT, NEGLIGENCE OR OTHER TORTIOUS ACTION, EVEN IF ACCF HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, RESULTING FROM: (i) THE USE OR INABILITY TO USE THE PRODUCT, (ii) THE COST OF ANY SUBSTITUTE PRODUCTS AND/OR SERVICES RESULTING FROM ANY PRODUCTS, DATA, INFORMATION OR SERVICES OBTAINED OR WHICH YOU WERE UNABLE TO OBTAIN OR TRANSACTIONS EFFECTED OR FAILED TO BE EFFECTED, (iii) THE USE OR INABILITY TO USE ANY THIRD PARTY APPLICATIONS CONTAINED WITHIN THE PRODUCT, OR (iv) ANY MATTER OTHERWISE RELATED TO YOUR USE OF THE PRODUCT.
Release of Liability
You assume all risks associated with use of the Product including, but not limited to any harm, injury or damages resulting directly or indirectly from the use of the Product, all such risks being known and understood by You. In consideration of your use of the Product, You, for yourself and anyone entitled to act on your behalf, waive and forever release ACCF, its officers, trustees, employees, representatives and successors from all claims and liabilities of any kind arising out of your use or misuse of the Product.
Indemnification
You hereby agree to indemnify, save and hold ACCF, its directors, officers, shareholders, parents, subsidiaries, affiliates, agents and licensors harmless from and against any and all claims, liability, losses, damages and costs, including, without limitation, reasonable attorneys' fees and costs, arising out of your use or misuse of the Product or Content, or any violation of this Agreement. ACCF assumes the right, at your expense, to assume the exclusive defense and control of any matter for which you are required to indemnify ACCF, and you agree to cooperate with ACCF’s defense of these claims. ACCF will use reasonable efforts to notify you of any such claim, action, or proceeding upon becoming aware of it.
Disclaimer of Warranties
THE PRODUCT AND CONTENT ARE PROVIDED ON AN "AS IS" AND "AS AVAILABLE" BASIS. ACCF AND ITS SUPPLIERS EXPRESSLY DISCLAIM ALL WARRANTIES OF ANY KIND WITH RESPECT TO THE PRODUCT OR CONTENT, WHETHER EXPRESS OR IMPLIED, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT. ACCF MAKES NO WARRANTY THAT THE PRODUCT AND/OR ANY CONTENT THEREIN WILL MEET YOUR REQUIREMENTS, OR WILL BE UNINTERRUPTED, TIMELY, SECURE, CURRENT, ACCURATE, COMPLETE OR ERROR-FREE OR THE RESULTS THAT MAY BE OBTAINED BY USE OF THE PRODUCT OR ANY CONTENT THEREIN WILL BE ACCURATE OR RELIABLE. YOU UNDERSTAND AND ACKNOWLEDGE THAT YOUR SOLE AND EXCLUSIVE REMEDY WITH RESPECT TO ANY DEFECT IN OR DISSATISFACTION WITH THE PRODUCT IS TO CEASE ITS USE.
The Content on the Product is presented as an educational service intended for licensed healthcare professionals. While the Content in the Product is about specific medical and healthcare issues, the Content is not a substitute for or replacement of personalized medical advice and is not intended to be used as the sole basis for making individualized medical or health-related decisions.
The views and opinions expressed are those of the contributing authors and editors and do not necessarily represent the views of the ACCF. The material is not intended to present the only, or necessarily best, methods or procedures for the medical situations addressed, but rather is intended to represent an approach, view, statement or opinion.
Any reference to a specific therapy or commercial product in this Product does not constitute a guarantee or endorsement by ACCF of the quality or value of such therapy or product or any claims made by the manufacturer of such therapy or commercial product.
In addition, any statements about such therapy or commercial products are solely based on published clinical prediction rules and estimates of drug treatment effects from published clinical studies and do not represent an ACCF endorsement or evaluation of these products.
Force Majeure
ACCF will be excused from performance under this Agreement and will not be liable or considered in default under this Agreement in the event that the Product is unavailable for any period of time, or if ACCF is otherwise unable to perform its obligations hereunder, in whole or in part, as a result of a Force Majeure Event. For purposes of this Section, "Force Majeure Event" means an event or series of events caused by or resulting from any of the following: (1) weather conditions or other elements of nature or acts of God; (2) government regulation; (3) quarantines or embargoes; (4) telecommunications, network, computer, server or Internet downtime; (5) unauthorized access to ACCF's information technology systems by third parties; or (6) any other causes beyond the reasonable control of ACCF.
No Assignment
This Agreement is personal to You, and You may not assign your rights or obligations to anyone.
No Waiver
Neither failure nor delay on the part of any party to exercise any right, remedy, power or privilege hereunder nor course of dealing between the parties shall operate as a waiver thereof, or of the exercise of any other right, remedy, power or privilege. No term of this Agreement shall be deemed waived, and no breach consented to, unless such waiver or consent shall be in writing and signed by the party claimed to have waived or consented. No waiver of any rights or consent to any breaches shall constitute a waiver of any other rights or consent to any other breach.
Severability
If any provision in this Agreement is held invalid or unenforceable under applicable law, the remaining provisions shall continue in full force and effect.
Governing Law
This Agreement will be governed by and construed exclusively in accordance with the laws of the District of Columbia, USA, without regard to its conflicts of law principles and, to the extent applicable, the federal laws of the United States. If a dispute arises between ACCF and You, You hereby agree to submit such dispute to non-binding mediation, followed by binding arbitration, if necessary. Both the mediation and arbitration will be conducted by JAMS applying the laws of the District of Columbia without regard to its conflicts of laws principles and in the District of Columbia as venue.
Certification
I hereby certify that I understand and agree to the terms stated in this Agreement and that this Agreement applies to my initial use of the Product and all other subsequent uses of the Product.
BY USING THIS PRODUCT, I HEREBY AFFIRM THAT I HAVE READ, FULLY UNDERSTAND, AND AGREE TO THE ABOVE STATEMENTS.
Welcome to the News feature of the ManageMR app. Check this tab for relevant research and articles from the medical community, as well as updates on related guidelines, tools, and events from the American College of Cardiology.
Below are suggested next steps for this patient based on the entered indications. Indications collected in this app represent only those covered by ACC/AHA/HFSA guidelines, and should serve as a starting point. Final treatment decisions should be made after a full evaluation of the patient and discussion of patient preferences. In addition, the scope of this app focuses on pharmacological treatment for HFrEF. However, medical therapy should be considered and implemented as just one component of the comprehensive management of a heart failure patient, along with suitable lifestyle management, specialty referrals, and any other treatment as needed.
To help optimize use of medical therapy, review expert consensus guiding principles.